1. Introduction {#sec1}
===============

Liver fibrosis is the result of an excessively exuberant wound healing response to chronic hepatic damage caused by imbalance between extracellular matrix (ECM) production and degradation. ECM overproduction caused by chronic damage leads to progressive loss of hepatic parenchyma and a progressive advance to cirrhosis [@bib1], [@bib2]. Activated hepatic stellate cells (HSCs) are one of the major executors of ECM accumulation in the liver. In their quiescent state, HSCs reside in the perisinusoidal space of Disse and store vitamin A. Repeated liver injury induces the transdifferentiation of quiescent HSCs into proliferative, contractile, and fibrogenic myofibroblast-like cells [@bib2]. Evidence indicates that liver fibrosis is a dynamic, reversible process, and thus, reducing numbers of activated HSCs is regarded as a critical strategy for reversing liver fibrogenesis [@bib2], [@bib3]. Although no drug has been approved for the treatment of liver fibrosis, it has been reported that several natural products, including berberine and guggulsterone, can cause the apoptosis of activated HSCs and reduce liver fibrosis in experimental models [@bib4], [@bib5].

AMP-activated protein kinase (AMPK), an evolutionarily conserved heterotrimeric Ser/Thr kinase, is considered a master regulator of nutritional status and energy homeostasis and is activated by several upstream kinases, including liver kinase B1 (LKB1) [@bib6], [@bib7]. AMPK activation in liver reduces lipid synthesis by inducing the phosphorylation of acetyl-CoA carboxylase (ACC), decreases protein metabolism by inhibiting mammalian target of rapamycin complex 1 (mTORC1), induces autophagy by activating unc-51-like protein kinase 1, and protects cells and mitochondria from oxidative stress [@bib7], [@bib8], [@bib9]. Thus, AMPK activation in liver relieves metabolic imbalances caused by alcohol intake or high calorie diet and protects tissues from toxic stimuli. Interestingly, activated AMPK attenuates liver fibrosis by inhibiting the proliferation of activated HSCs and ECM accumulation [@bib10], [@bib11], [@bib12]. Although it has been reported that AMPK activation leads to HSC apoptosis [@bib4], [@bib13], the relationship between AMPK activation and HSC apoptosis remains to be further established.

Ginseng, the root of *Panax ginseng* Meyer, has been used as adaptogenic agent for centuries in Korea, and modern science has shown that ginseng saponins (ginsenosides) are major active ingredients of ginseng. The ginsenosides are classified as dammarane-type, ocotillol-type, or oleanane-type oligoglycosides, and the most abundant dammarane-type ginsenosides can be further classified as protopanaxadiol (PPD) or protopanxatriol (PPT) types [@bib14]. Although ginsenosides have been credited with the diverse pharmacological activities of ginseng [@bib15], they are poorly absorbed in the gastrointestinal tract, and thus, the compounds responsible for the effects of orally administered ginseng are believed to be metabolites produced in the gastrointestinal tract [@bib16], [@bib17], [@bib18], [@bib19].

Studies have shown that ginseng and ginsenosides ameliorate diverse liver diseases by inducing the activation of AMPK [@bib20], [@bib21], [@bib22], [@bib23]. In addition, certain ginsenosides have been reported to inhibit liver fibrosis [@bib24], [@bib25] and to induce HSC apoptosis [@bib26]. In a previous study, we found Korean Red Ginseng inhibited liver fibrosis induced by carbon tetrachloride in mice and decreased the expressions of transforming growth factor-β (TGF-β)-dependent fibrogenic genes in HSCs [@bib27]. Although ginseng may regress fibrosis in liver, the major ginsenosides that contribute to reductions in activated HSC numbers have yet to be identified. Thus, in the present study, we sought to identify the ginsenosides responsible for reducing the numbers of HSC and the underlying molecular mechanisms involved.

2. Materials and methods {#sec2}
========================

2.1. Reagents {#sec2.1}
-------------

Korean Red Ginseng extract (RGE) was kindly provided by KT&G Central Research Institute (Daejeon, Korea), as described previously [@bib27]. Ginsenosides (Rb1, Rb2, Rc, 20*S*-Rg3, 20*R*-Rg3, Re, Rg1) and aglycosylated metabolites \[compound K (Comp. K), 20*S*-PPT, 20*R*-PPD, and 20*S*-PPD\] were purchased from Ambo Institute (Daejeon, Korea) ([Fig. 1](#fig1){ref-type="fig"}). Compound C (an inhibitor of AMPK) and STO-609 (an inhibitor of Ca^2+^/calmodulin-dependent protein kinase kinase β, CAMKKβ) were supplied by Calbiochem (San Diego, CA, USA). Anti-poly(ADP-ribose)polymerase (PARP), anti-procaspase-3, anti-phosphorylated AMPK (Thr172), anti-phosphorylated ACC (Ser79), anti-ACC, anti-phosphorylated LKB1 (Ser428), anti-LKB1, anti-Bcl-2, anti-glial fibrillary acidic protein (GFAP), and horseradish peroxidase-conjugated secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Anti-Bax and anti-AMPK antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), *N*-acetyl-[l]{.smallcaps}-cysteine (NAC), rhodamine123, 2′,7′-dichlorofluorescein diacetate (DCFH-DA), anti-α-smooth muscle actin (α-SMA) antibody, anti-β-actin antibody, and other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).Fig. 1Chemical structures of ginsenosides and aglycosylated metabolites. Numerical superscripts indicate the carbons at glycosidic bonds. Ara(f), arabinofuranose; Ara(p), arabinopyranose; Comp. K, compound K; Glc, glucose; PPD, protopanaxadiol; PPT, protopanaxatriol; Rha, rhamnose.

2.2. Cell culture, isolation of murine primary HSCs, and treatment {#sec2.2}
------------------------------------------------------------------

LX-2 cells (a human immortalized semi-activated HSCs cell line) were kindly provided by Dr S.L. Friedman (Mount Sinai School of Medicine, New York, NY, USA). Cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS), 2mM [l]{.smallcaps}-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO~2~. HSC isolation was conducted according to national regulations regarding the use and welfare of laboratory animals, and was approved by the Institutional Animal Care and Use Committee at Daegu Haany University (Approval No. DHU2016-061). Male ICR mice were perfused using pronase/collagenase, and primary HSCs were isolated by gradient centrifugation, as previously described [@bib28]. Isolated cells were cultured on six-well plate in Dulbecco's modified Eagle's medium containing 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin for 6 d to acquire activated HSCs. The purity of isolated HSCs was confirmed by UV positivity using a fluorescent microscope (Eclipse Ti-U; Nikon, Kanagawa, Japan), and phenotypic changes during HSC activation were verified by GFAP and α-SMA immunoblotting, as previously described [@bib13], [@bib28]. RGE and NAC were dissolved in water. Ginsenosides, DCFH-DA, rhodamine123, compound C, and STO-609 were dissolved in dimethyl sulfoxide. For all experiments, cells were grown until 80--90% confluent, incubated in medium without FBS for 12 h, and then exposed to RGE or ginsenoside for the indicated times. Untreated cells were used as controls.

2.3. Cell viability assay {#sec2.3}
-------------------------

To examine the cytotoxicities of ginsenosides, cells were plated at 5 × 10^4^ cells/well in 24-well plates, serum-starved for 12 h, and then treated with 0.3--10 mg/mL of RGE or 1--10μM of ginsenosides for the indicated times. After treatments, viable cells were stained with MTT (0.5 mg/mL, 4 h), and viabilities were assessed as previously described [@bib8].

2.4. Preparation of whole cell lysates and immunoblot analysis {#sec2.4}
--------------------------------------------------------------

Cells were lysed in radioimmunoprecipitation buffer containing Xpert protease inhibitor cocktail (GenDEPOT, Barker, TX, USA), sodium fluoride (1mM), β-glycerophosphate (1mM), sodium orthovanadate (1mM), and sodium pyrophosphate (2.5mM). After incubation for 30 min on ice, cell lysates were collected by centrifugation at 15,000*g* for 30 min. Protein concentrations were determined using a bicinchoninic acid assay kit (Thermo, Rockford, IL, USA). Equal amounts of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes (Amersham Biosciences, Buckinghamshire, UK). Immunoreactive proteins of interest were visualized using an enhanced chemiluminescence detection kit (Amersham Biosciences). Equal protein sample loadings in gels were verified by β-actin immunoblotting. Immunoblot intensities were quantified by densitometric analysis (Image J, rsb.info.nih.gov/ij).

2.5. Measurement of intracellular H~2~O~2~ production {#sec2.5}
-----------------------------------------------------

The levels of intracellular H~2~O~2~ production were determined by measuring increases in dichlorofluorescein fluorescence. After treating LX-2 cells with 20*S*-PPD for 24 h, cells were stained with 20μM of DCFH-DA for 1 h. Dichlorofluorescein fluorescence was measured using an automated microplate reader (Tecan Infinite 200 PRO, Männedorf, Switzerland) at excitation/emission wavelengths of 485 nm/530 nm.

2.6. Measurement of reduced glutathione {#sec2.6}
---------------------------------------

LX-2 cells were treated with 20*S*-PPD for 24 h, and levels of reduced glutathione (GSH) were determined by using a GSH BIOXYTECH GSH-400 kit (Oxis International Inc., Portland, OR, USA). Absorbance at 405 nm was monitored using a microplate reader (Tecan).

2.7. Measurement of lactate dehydrogenase activity {#sec2.7}
--------------------------------------------------

Lactate dehydrogenase (LDH) activities in media were measured using an LDH assay kit (Cayman, Ann Arbor, MI, USA). Briefly, 20*S*-PPD-treated media were incubated for 30 min at room temperature with an assay buffer containing LDH diaphorase, lactic acid, NAD^+^, and tetrazolium salt. Absorbance at 490 nm was then measured using a microplate reader (Tecan).

2.8. Flow cytometric analyses {#sec2.8}
-----------------------------

Mitochondrial membrane permeability (MMP) was assessed using rhodamine123, a membrane permeable cationic fluorescent dye [@bib8]. Cells were treated with 10μM of 20*S*-PPD for 24 h, stained with 0.05 μg/mL rhodamine123 for 1 h, and harvested by trypsinization. For some experiments, cells were pretreated either with 10mM of NAC or 3μM of compound C for 1 h, and then exposed to 10μM of 20*S*-PPD for 24 h. A dead cell apoptosis kit (Invitrogen, Carlsbad, CA, USA) was used to quantify subpopulations of apoptotic cells. Changes in MMP and dead cell subpopulations were determined using a flow cytometer (Partec, Münster, Germany). A total of 10,000 events were recorded during each analysis.

2.9. Caspase-3/-7 activities assay {#sec2.9}
----------------------------------

Caspase-3/-7 activities in cell lysates were determined using a Caspase-Glo 3/7 assay kit (Promega, Madison, WI, USA). 20*S*-PPD-treated LX-2 cells were harvested and resuspended in phosphate-buffered saline (PBS), and Caspase-Glo 3/7 reagent was added. Cell lysates were then incubated at room temperature for 2 h, and luminescence intensities were measured using a GloMax 20/20 luminometer (Promega). Measured luminescence intensities were normalized with respect to the protein contents of lysates.

2.10. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining {#sec2.10}
---------------------------------------------------------------------------

After treatment with 3μM or 10μM of 20*S*-PPD for 18 h, LX-2 cells were stained using an *In Situ* Apoptosis Detection Kit (Abcam, Cambridge, MA, USA). Briefly, cells were washed with PBS, fixed in PBS containing 4% paraformaldehyde, rehydrated in Tris-buffered saline, and permeabilized by adding 20 mg/mL of protease K. After inactivating endogenous peroxidase, cells were labeled with terminal deoxynucleotidyl transferase, incubated with streptoavidin--horseradish peroxidase conjugate, and then developed using diaminobenzidine. The stained cells were observed under a light microscope (Eclipse Ti-U; Nikon, Kanagawa, Japan).

2.11. Small interfering RNA transfection {#sec2.11}
----------------------------------------

Scrambled siRNA (si-Con) and small interfering RNA (siRNA) directed against LKB1 (si-LKB1) were supplied by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cells were transfected with siRNA (100 pmol each) for 24 h by using Fugene HD transfection reagent (Invitrogen), and then treated with 20*S*-PPD for the indicated times.

2.12. Statistical analysis {#sec2.12}
--------------------------

One-way analysis of variance was used to determine the significance level of differences between multiple group means, and unpaired Student *t* test was used to determine the significance level of differences between the means of two groups. A *p* value \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. 20S-PPD decreased HSC viability {#sec3.1}
------------------------------------

To explore the mechanistic basis of the antifibrotic effect of RGE, we treated LX-2 cells with 0.3--10 mg/mL of RGE, and then measured cell viability using an MTT assay. Exposure to RGE (1--10 mg/mL) for 24 h significantly and concentration-dependently decreased cell viability as compared with untreated control cells ([Fig. 2](#fig2){ref-type="fig"}A, left). When LX-2 cells were treated with 10 mg/mL of RGE for 6--48 h, cell viabilities were time-dependently decreased by RGE treatment ([Fig. 2](#fig2){ref-type="fig"}A, right). Because treatment with RGE for 24 h is sufficient incubation time to show differences in LX-2 cell viabilities, cells were treated with major ginsenosides and aglycosylated metabolites for 24 h to identify the ginsenoside responsible for RGE-mediated HSC cytotoxicity. Treatment with PPD-type ginsenosides (Rb1, Rb2, Rc, and 20*R*-Rg3) or PPT-type ginsenosides (Re and Rg1) at concentrations up to 10μM for 24 h did not affect LX-2 cell viability ([Figs. 2](#fig2){ref-type="fig"}B and 2C). However, treatment with the PPD-type ginsenoside 20*S*-Rg3 (10μM) significantly decreased cell viability. In addition, treatments with aglycosylated metabolites (Comp. K, 20*R*-PPD, and 20*S*-PPD) for 24 h also concentration-dependently reduced LX-2 cell viability, whereas treatment with 20*S*-PPT did not ([Fig. 2](#fig2){ref-type="fig"}D). The IC~50~ values of Comp. K, 20*R*-PPD, and 20*S*-PPD were 3.39 ± 0.87μM, 8.52 ± 0.59μM, and 2.05 ± 0.59μM, respectively.Fig. 2Effects of Korean Red Ginseng extract (RGE) and ginsenosides on cell viability. (A) After serum starvation for 12 h, LX-2 cells were incubated with 0.3--10 mg/mL of RGE for 24 h (left) or 10 mg/mL of RGE for 6--48 h (right). (B) LX-2 cells were treated with 1--10μM of PPD-type ginsenosides for 24 h. (C) LX-2 cells were treated with 1--10μM of PPT-type ginsenosides for 24 h. (D) LX-2 cells were treated with 1--10μM of aglycosylated metabolites. Cell viabilities were measured using an MTT assay. Data represent the means ± SDs of three separate experiments. Significant versus untreated controls; \* *p* \< 0.05, \*\* *p* \< 0.01. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; SD, standard deviation; PPD, protopanaxadiol; PPT, protopanaxatriol.

Ginsenoside Rb1 has an O-linked di-glucose residue at C3 and C20 on its PPD scaffold. By contrast, the ginsenoside metabolite Comp. K has a hydroxyl group at C3 and an O-linked glucose at C20, and 20*S*-PPD has only hydrogen at C3 and C20 ([Fig. 1](#fig1){ref-type="fig"}). To examine the effect of ginsenoside aglycosylation on LX-2 cell viability, we treated cells with Rb1, Comp. K, or 20*S*-PPD (3μM each). As was expected, treatment time with Rb1 (3μM) for up to 24 h did not decrease cell viability. When LX-2 cells were incubated with 3μM of 20*S*-PPD, cell viability was reduced significantly at 6 h, and this then gradually decreased. However, cell viability started to decrease significantly at 12 h after LX-2 cells were treated with 3μM of Comp. K ([Fig. 3](#fig3){ref-type="fig"}A). The viabilities of 20*S*-PPD- and Comp. K-treated cells at 24 h were 14.75 ± 1.00% and 55.40 ± 5.17% of that of controls, respectively. Next, we isolated primary HSCs from ICR mice and cultivated them for 6 d to activate the cells. Cell purity and identity were confirmed by UV positivity, GFAP (a marker of quiescent HSCs), and α-SMA (a marker of activated HSCs) immunoblotting ([Fig. 3](#fig3){ref-type="fig"}B, upper). When primary activated HSCs were treated with Rb1, Comp. K, or 20*S*-PPD (3μM each) for 24 h, 20*S*-PPD was found to reduce α-SMA protein levels ([Fig. 3](#fig3){ref-type="fig"}B, lower). In addition, 20*S*-PPD (3μM, 24 h) had the most potent cytotoxic effect against primary activated HSCs ([Fig. 3](#fig3){ref-type="fig"}C).Fig. 3Effects of aglycosylated metabolites on HSC viability. (A) LX-2 cells were treated with Rb1, Comp. K, or 20*S*-PPD (3μM each) for the indicated times, and then cell viabilities were measured. (B) Primary HSCs were isolated from ICR mice and continuously cultivated for 6 d to acquire activated HSCs. Purity and phenotypic changes of activated HSCs were confirmed by UV positivity, and by immunoblotting for GFAP and α-SMA (upper). Primary activated HSCs were treated with 3μM of Rb1, Comp. K, or 20*S*-PPD for 24 h, α-SMA protein levels were assessed by immunoblotting. Equal protein loadings were verified by immunoblotting for β-actin (lower). (C) Effect of Rb1, Comp. K, or 20*S*-PPD on the cell viabilities of primary activated HSCs. Data represent the means ± SDs of three separate experiments. Significant versus untreated controls; \* *p* \< 0.05, \*\* *p* \< 0.01; significant as compared between Comp. K- and 20*S*-PPD-treated cells, ^\#\#^*p* \< 0.01. Comp. K, compound K; GFAP, glial fibrillary acidic protein; HSC, hepatic stellate cell; PPD, protopanaxadiol; SMA, smooth muscle actin; SD, standard deviation.

3.2. 20S-PPD promoted oxidative stress {#sec3.2}
--------------------------------------

To determine whether oxidative stress was involved in 20*S*-PPD-mediated HSC death, LX-2 cells were pretreated with NAC (10mM; a representative antioxidant) and then incubated with 10μM of 20*S*-PPD for 24 h. We found that 20*S*-PPD-mediated cytotoxicity was significantly inhibited by NAC pretreatment ([Fig. 4](#fig4){ref-type="fig"}A). Next, we monitored intracellular H~2~O~2~ production using DCFH-DA. Treatment with 1--10μM of 20*S*-PPD for 24 h increased intracellular H~2~O~2~ production in a concentration-dependent manner. However, NAC pretreatment completely abolished the H~2~O~2~ accumulation induced by 20*S*-PPD ([Fig. 4](#fig4){ref-type="fig"}B). We also measured the level of reduced GSH (a major endogenous antioxidant that regulates redox homeostasis by scavenging reactive oxygen species). Intracellular concentrations of reduced GSH were significantly diminished after treatment of LX-2 cells with 3μM or 10μM of 20*S*-PPD for 24 h ([Fig. 4](#fig4){ref-type="fig"}C). In addition, we further investigated whether reactive oxygen species generation by 20*S*-PPD was mediated by mitochondrial membrane dysfunction. We observed that 20*S*-PPD (10μM) significantly increased LX-2 cell populations with low rhodamine123 fluorescence intensity as compared with controls, and that this 20*S*-PPD-induced change was prevented by NAC pretreatment (10mM) ([Fig. 4](#fig4){ref-type="fig"}D). Furthermore, LX-2 cells treated with 20*S*-PPD released LDH to medium in a concentration-dependent manner ([Fig. 4](#fig4){ref-type="fig"}E).Fig. 4Induction of oxidative stress by 20*S*-PPD. (A) Effect of NAC on 20*S*-PPD-mediated cytotoxicity. LX-2 cells were pretreated with 10mM of NAC for 1 h and then further incubated with 10μM of 20*S*-PPD for 24 h. (B) H~2~O~2~ production by 20*S*-PPD. (C) GSH contents of cells treated with 1--10μM of 20*S*-PPD for 24 h. (D) MMPs. Treated cells were stained with rhodamine123 (0.05 μg/mL) and then MMPs were assessed (left). Cell populations that exhibited low rhodamine123 intensity were quantified by flow cytometry (right). (E) LDH leakage. Conditioned media of cells treated with 1--10μM of 20*S*-PPD were collected, and LDH activities were measured. Data represent the means ± SDs of three separate experiments. Significant versus untreated controls or treatment with NAC alone, \* *p* \< 0.05, \*\* *p* \< 0.01; significant as compared between 20*S*-PPD alone and 20*S*-PPD plus NAC treated cells, ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01. GSH, glutathione; LDH, lactate dehydrogenase; MMP, mitochondrial membrane permeability; NAC, *N*-acetyl-[l]{.smallcaps}-cysteine; PPD, protopanaxadiol; SD, standard deviation.

3.3. 20S-PPD induced HSC apoptosis {#sec3.3}
----------------------------------

To determine the type of cell death induced by 20*S*-PPD, LX-2 cells were treated with 3μM or 10μM of 20*S*-PPD for 24 h and double stained with fluorescein isothiocyanate-conjugated annexin V and propidium iodide (PI). Cell subpopulations were then investigated by flow cytometry ([Fig. 5](#fig5){ref-type="fig"}A). The results showed that 20*S*-PPD concentration-dependently increased the proportion of early apoptotic cells (annexin V-positive and PI-negative stained cells). Proportions of early apoptosis were 25.12 ± 12.47% and 63.03 ± 12.70% in cells treated with 3μM or 10μM of 20*S*-PPD, respectively. Next, we monitored the expression levels of apoptosis-related proteins to confirm apoptosis induction by 20*S*-PPD. When cells were treated with Comp. K or 20*S*-PPD (both at 3μM) for 24 h, 20*S*-PPD was found to cause more PARP cleavage than Comp. K. Although Comp. K treatment tended to increase PARP cleavage as compared with controls, no statistical difference was observed ([Fig. 5](#fig5){ref-type="fig"}B). Furthermore, 20*S*-PPD increased Bax expression, reduced the expressions of procaspase-3 and Bcl-2 in a concentration-dependent manner ([Fig. 5](#fig5){ref-type="fig"}C), and significantly increased caspase-3/-7 activities ([Fig. 5](#fig5){ref-type="fig"}D) and transferase dUTP nick end labeling (TUNEL) staining intensities of LX-2 cells ([Fig. 5](#fig5){ref-type="fig"}E).Fig. 5Induction of apoptosis by 20*S*-PPD. (A) Flow cytometry analyses of cells double stained with fluorescein isothiocyanate-conjugated annexin V and PI. LX-2 cells were treated with 3μM or 10μM of 20*S*-PPD for 24 h. Percentages of healthy (low annexin V and low PI stained cells), early apoptotic (high annexin V and low PI stained cells), late apoptotic (high annexin V and high PI stained cells), and necrotic (low annexin V and high PI stained cells) cells were shown in the bar graph. (B) PARP cleavage. LX-2 cells were treated with 20*S*-PPD or Comp. K (3μM each) for 24 h and cell lysates were immunoblotted for PARP. (C) Expressions of apoptosis-related proteins. LX-2 cells were treated with 3μM or 10μM 20*S*-PPD for 24 h and immunoblotted for proteins associated with apoptosis. (D) Caspase-3/-7 activities. (E) TUNEL staining. LX-2 cells were treated with 3μM or 10μM 20*S*-PPD for 18 h and then stained by TUNEL. The relative expression levels of proteins were determined by scanning densitometry (B and C). Data represent the means ± SDs of three separate experiments. Significant versus untreated controls, \* *p* \< 0.05, \*\* *p* \< 0.01; significant as compared between 20*S*-PPD and Comp. K treated cells, ^\#\#^*p* \< 0.01. Comp. K, compound K; PARP, poly(ADP-ribose)polymerase; PI, propidium iodide; PPD, protopanaxadiol; SD, standard deviation; TUNEL, transferase dUTP nick end labeling.

3.4. AMPK activation was involved in 20S-PPD-mediated apoptosis {#sec3.4}
---------------------------------------------------------------

To determine whether 20*S*-PPD activates AMPK in HSCs, we monitored the phosphorylations of AMPK and ACC (a downstream substrate of AMPK) in LX-2 cells. The phosphorylations of AMPK and ACC were both increased by 20*S*-PPD at concentrations of 1--10μM, whereas 20*S*-PPD did not affect the expression levels of AMPK and ACC ([Fig. 6](#fig6){ref-type="fig"}A, upper). Maximum AMPK phosphorylation was observed after treatment with 1μM of 20*S*-PPD for 6 h, and this phosphorylation was sustained for 24 h ([Fig. 6](#fig6){ref-type="fig"}A, lower). Consistently, treatment with 20*S*-PPD increased the phosphorylations of AMPK and ACC more than the same concentrations of Rb1 or Comp. K in LX-2 cells and primary activated HSCs ([Fig. 6](#fig6){ref-type="fig"}B). To investigate the role of AMPK activation in 20*S*-PPD-induced HSCs apoptosis, AMPK activation was blocked by pretreating LX-2 cells with compound C, and 20*S*-PPD-mediated cytotoxicity was then monitored. Cell viability results showed that pretreatment with compound C (1μM or 3μM) significantly inhibited the 20*S*-PPD-induced apoptosis of LX-2 cells ([Fig. 6](#fig6){ref-type="fig"}C, lower). Inhibition of AMPK activity by compound C was confirmed by immunoblotting ([Fig. 6](#fig6){ref-type="fig"}C, upper). Treatment with compound C alone did not alter cell viability (data not shown). Furthermore, mitochondrial impairment induced by 20*S*-PPD was also significantly attenuated by compound C pretreatment ([Fig. 6](#fig6){ref-type="fig"}D).Fig. 6Activation of AMPK by 20*S*-PPD. (A) AMPK activation. LX-2 cells were treated with 1--10μM of 20*S*-PPD for 6 h (upper) or 1μM of 20*S*-PPD for 1--24 h (lower). Levels of phosphorylated AMPK and ACC in cell lysates were assessed by immunoblotting. Equal protein loadings was confirmed by immunoblotting for β-actin. Results were confirmed by repeated experiments. (B) Effect of aglycosylated ginsenosides on AMPK activation. LX-2 cells (upper) or primary activated HSCs (lower) were treated with Rb1, Comp. K or 20*S*-PPD (1μM each) for 6 h. (C) The effects of compound C on 20*S*-PPD-mediated cytotoxicity. LX-2 cells were pretreated with 1μM or 3μM of compound C for 1 h, and subsequently exposed to 1--10μM of 20*S*-PPD for 24 h. (D) Effect of compound C on 20*S*-PPD-mediated mitochondrial dysfunction. LX-2 cells were pretreated with 3μM of compound C for 1 h and then incubated with 10μM of 20*S*-PPD for 24 h. Data represent the means ± SDs of three separate experiments. Significant versus untreated controls or treatment with compound C alone, \*\**p* \< 0.01; significant as compared between 20*S*-PPD alone and 20*S*-PPD plus compound C treated cells, ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; Comp. K, compound K; HSCs, hepatic stellate cells; PPD, protopanaxadiol; SD, standard deviation.

3.5. 20S-PPD phosphorylated AMPK by activating LKB1 {#sec3.5}
---------------------------------------------------

To identify the upstream kinase involved in 20*S*-PPD-mediated AMPK activation, we investigated whether LKB1 (an upstream kinase of AMPK) was phosphorylated by 20*S*-PPD. LKB1 phosphorylation started to increase at 6 h after treating LX-2 cells with 1μM of 20*S*-PPD and was sustained for up to 24 h ([Fig. 7](#fig7){ref-type="fig"}A), which paralleled 20*S*-PPD-induced AMPK phosphorylation ([Fig. 6](#fig6){ref-type="fig"}A). Transfection with LKB1 siRNA decreased 20*S*-PPD-mediated AMPK phosphorylation ([Fig. 7](#fig7){ref-type="fig"}B), and inhibited 20*S*-PPD-mediated cytotoxicity ([Fig. 7](#fig7){ref-type="fig"}C). However, chemical inhibition of CAMKKβ by STO-609 had no effect on 20*S*-PPD-mediated AMPK phosphorylation or cytotoxicity ([Fig. 7](#fig7){ref-type="fig"}D).Fig. 7Role of LKB1 on 20*S*-PPD-mediated AMPK activation. (A) LKB1 phosphorylation. LX-2 cells were treated with 20*S*-PPD (1μM) for the indicated times. Levels of phosphorylated LKB1 in cell lysates were measured by immunoblotting. Equal protein loadings were confirmed by immunoblotting for LKB1. (B) Effect of LKB1 knockdown on 20*S*-PPD-mediated AMPK activation. LX-2 cells were transfected with scrambled siRNA (si-Con) or LKB1 siRNA (si-LKB1) and then treated with 20*S*-PPD (10μM) for 6 h. (C) Effect of LKB1 knockdown on 20*S*-PPD-mediated cytotoxicity. si-LKB1 transfected cells were treated with 10μM of 20*S*-PPD for 24 h and cell viabilities were measured. (D) Effect of STO-609 on 20*S*-PPD-mediated cytotoxicity. LX-2 cells were pretreated with 1 μg/mL STO-609 and then exposed to 10μM of 20*S*-PPD for 6 h (upper) or to 1--10μM of 20*S*-PPD for 24 h (lower). Data represent the means ± SDs of three separate experiments. Significant versus untreated controls, \**p* \< 0.05, \*\**p* \< 0.01; significant as compared between 20*S*-PPD-treated cells, ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; LKB1, liver kinase B1; PPD, protopanaxadiol; N.S., not significant; SD, standard deviation.

4. Discussion {#sec4}
=============

It is generally accepted that the diverse pharmacological activities of *P. ginseng* are derived from a group of steroidal saponins, the ginsenosides [@bib15]. When *P. ginseng* is orally administered, ginsenosides cannot be easily absorbed into tissues because of their hydrophilicities. Thus, ginsenosides are converted into metabolites in the gastrointestinal tract by acid hydrolysis or intestinal microflora. It has been reported that the fully aglycosylated metabolite, PPD, can be produced from ginseng extract, Rb1, Rg3, or Comp. K by intestinal microflora [@bib16], [@bib18], [@bib19], [@bib29], and that aglycosylated metabolites are more potent than their parent compounds [@bib26], [@bib29], [@bib30]. Studies have shown that 20*S*-PPD inhibits the growth of *Helicobacter pylori* [@bib29], attenuates the progression and growth of castration-resistant prostate cancer [@bib31], enhances the sensitivity of chemotherapy against colorectal cancer [@bib16], and protects neurons from permanent focal cerebral ischemic damage [@bib32]. Although Park et al [@bib26] reported that Comp. K triggers apoptosis in T-HSC/Cl-6 cells (a rat-derived HSC line), the effects of other ginsenosides on HSCs remain to be established.

Among the 11 ginsenosides and aglycosylated metabolites tested, we found that 20*S*-PPD exhibited the greatest cytotoxic activity in HSCs ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}). Our results indicate that 20*S*-PPD increased H~2~O~2~ production, depleted GSH levels, impaired MMP, and enhanced LDH leakage. Furthermore, pretreatment with NAC attenuated 20*S*-PPD-mediated H~2~O~2~ production, mitochondrial dysfunction, and cytotoxicity ([Fig. 4](#fig4){ref-type="fig"}), indicating that oxidative stress is involved in HSC death. Oxidative stress changes the Bcl-2/Bax expression ratio and opens the mitochondrial permeability transition pore, which promotes caspase-dependent apoptosis [@bib33], [@bib34]. Caspase-3 and caspase-7 are executor caspases and are responsible for the cleavage of more than 100 different proteins including that of PARP [@bib35]. PARP cleavage causes defects in the DNA repair system and accelerates DNA fragmentation [@bib36]. In accord with previous reports, the present study shows that 20*S*-PPD concentration-dependently reduced the expression of Bcl-2 (an antiapoptotic protein), increased the expression of Bax (a pro-apoptotic protein), and enhanced caspase-3/-7 activities. In addition, 20*S*-PPD concentration-dependently increased PARP cleavage, TUNEL staining intensity, and the proportions of early apoptotic cells ([Fig. 5](#fig5){ref-type="fig"}). Moreover, 20*S*-PPD induced the cleavage of PARP more than Comp. K at same concentration ([Fig. 5](#fig5){ref-type="fig"}B), which suggests that the apoptotic activities of ginsenosides are potentiated by the loss of sugar moieties.

Accumulated evidence shows AMPK is a double-edged sword in terms of determining the fate of cells against a variety of stresses. Previously, we reported that AMPK activation by several natural products protects hepatocytes from oxidative stress [@bib8], [@bib37]. In addition, other groups have reported that AMPK activation attenuates hepatocytes apoptosis in different experimental models, such as tumor necrosis factor α-induced hepatitis and hepatic ischemia--reperfusion [@bib38], [@bib39]. However, AMPK activation in hepatocellular carcinoma cells causes cell cycle arrest and apoptosis [@bib40], [@bib41]. AMPK suppresses proliferation, migration, chemokine secretion, and profibrogenic genes expressions in HSCs [@bib10], [@bib11], [@bib12], [@bib42], [@bib43], which are the major phenotype changes observed during HSC activation [@bib3]. Blockage of AMPK has been reported to attenuate the ability of adiponectin to inhibit HSC proliferation [@bib11], [@bib12], and AMPK activation in HSCs degrades p300 coactivator, dissociates protein interactions between Smad3 and p300, and thereby inhibits the TGF-β-mediated expressions of ECM proteins [@bib10]. Furthermore, AMPK activation by curcumin in HSCs upregulates antioxidant and adipogenic genes by inducing peroxisome proliferator-activated receptor-γ coactivator-1α, and downregulates the expressions of profibrogenic genes by inhibiting aerobic glycolysis [@bib42], [@bib43].

Although several studies have suggested that AMPK activation leads to HSC apoptosis [@bib4], [@bib13], the relationship between AMPK activation and HSC apoptosis remains to be further established. The present results indicate that 20*S*-PPD was the most cytotoxic and that it also triggered AMPK phosphorylation in HSCs ([Fig. 3](#fig3){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}B). Moreover, 20*S*-PPD-mediated mitochondrial dysfunction and apoptosis were blocked in the presence of compound C (an AMPK inhibitor) ([Figs. 6](#fig6){ref-type="fig"}C and 6D). Therefore, our results imply that AMPK activation is involved in the 20*S*-PPD-mediated apoptosis of HSCs. mTORC1 is another regulator of cell growth in response to energy status or environmental stress [@bib44]. mTORC1 is a protein complex that contains mTOR, regulatory associated protein of mTOR (raptor), GβL, and PRAS40 [@bib44], [@bib45]. AMPK activation inhibits mTORC1 activity and that of its downstream kinase, p70 ribosomal S6 kinase, via the phosphorylation of raptor [@bib46]. Our supplementary results indicate that 20*S*-PPD increased the phosphorylation of raptor, decreased the GβL expression, and reduced levels of phosphorylated mTOR and S6 (a downstream substrate of p70 ribosomal S6 kinase) in LX-2 cells ([Fig. S1](#appsec1){ref-type="sec"}). Although identities of the downstream signaling molecules that regulate HSC apoptosis remain to be further identified, our findings suggest the involvement of mTORC1 inhibition in AMPK-mediated apoptosis induced by 20*S*-PPD.

Changes in AMP/ATP ratio and the activations of LKB1, CaMKK, protein kinase A, and TGF-β-activated kinase have been reported to regulate AMPK activity [@bib6], [@bib7], [@bib47]. Ginsenosides and aglycosylated metabolites activate AMPK via multiple upstream activators [@bib22]. It has been established that LKB1 activation by Rg1 or Rg2 inhibits hepatic glucose production [@bib23], [@bib48]. Comp. K decreases matrix methaloprotease-1 expression in fibroblasts by activating LKB1 [@bib30]. However, the activations of CaMKK by Comp. K or Rg3 induce the apoptosis of colon cancer cells and increase nitric oxide production in endothelial cells, respectively [@bib49], [@bib50]. In the present study, 20*S*-PPD increased LKB1 phosphorylation and concomitantly increased AMPK phosphorylation. In addition, AMPK phosphorylation and HSC apoptosis by 20*S*-PPD were attenuated in si-LKB1 transfected cells. However, the chemical inhibition of CaMKKβ by STO-609 did not decrease 20*S*-PPD-mediated AMPK phosphorylation or cytotoxicity in LX-2 cells ([Fig. 7](#fig7){ref-type="fig"}). Therefore, our results suggest that 20*S*-PPD activates AMPK in HSCs in an LKB1-dependent manner.

In conclusion, our results demonstrate that aglycosylation potentiates the cytotoxicities of ginsenosides against HSCs. Of the ginsenosides examined in the present study, 20*S*-PPD most potently induced the apoptosis of HSCs via LKB1-dependent AMPK activation. Taken together, these findings suggest that 20*S*-PPD is a potential therapeutic candidate for the prevention or treatment of liver fibrosis.
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The following is the supplementary data related to this article:

**Fig. S1**. Effect of 20*S*-PPD on mTOR signaling pathway. LX-2 cells were treated with 1μM of 20*S*-PPD for 1--24 h. Expression levels of the phosphorylated mTOR, phosphorylated raptor, GβL, and phosphorylated S6 in cell lysates were measured by immunoblotting. Results were confirmed by repeated experiments.

This study was supported by the National Research Foundation (NRF) of Korea funded by Korea government (MSIP) (Grant No. 2012 R1A5A2A42671316) and partly by a grant from Daegu Haany University Kylin Foundation in 2014.

Supplementary data related to this article can be found at [http://dx.doi.org/10.1016/j.jgr.2017.01.012](10.1016/j.jgr.2017.01.012){#intref0010}.

[^1]: These authors contributed equally to this work.
